Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 369.72M P/E - EPS this Y 0.90% Ern Qtrly Grth -
Income -141.77M Forward P/E -4.37 EPS next Y 54.00% 50D Avg Chg 11.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 41.00%
Dividend N/A Price/Book 2.29 EPS next 5Y - 52W High Chg -37.00%
Recommedations 1.60 Quick Ratio 8.33 Shares Outstanding 43.22M 52W Low Chg 162.00%
Insider Own 1.44% ROA -53.94% Shares Float 26.08M Beta 0.90
Inst Own 120.43% ROE -90.84% Shares Shorted/Prior 5.72M/5.68M Price 10.80
Gross Margin - Profit Margin - Avg. Volume 175,453 Target Price 30.17
Oper. Margin - Earnings Date Dec 5 Volume 302,251 Change 1.31%
About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

KalVista Pharmaceuticals, Inc. News
11/12/24 KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
11/05/24 KalVista Secures $184M Financing for Sebetralstat Launch
11/05/24 KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/04/24 DRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat
11/04/24 KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
11/04/24 KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
10/28/24 KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
10/18/24 KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
10/04/24 KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
10/02/24 High Growth Tech Stocks To Watch In The United States
09/30/24 KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
09/26/24 KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
09/10/24 KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
09/10/24 KalVista Appoints Brian Piekos as Chief Financial Officer
09/06/24 KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
09/05/24 KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
09/03/24 KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
08/29/24 KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium
08/15/24 KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema
08/10/24 Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
KALV Chatroom

User Image EMINENZ Posted - 2 days ago

$KALV buy level. 2bn drug about to be approved.

User Image Night_Owl_Biotech Posted - 3 days ago

The attachment documents the F2027 revenue multiple of 4 pre-commercial bios with active PDUFA dates including $APLT $KALV $HUMA & $MIST The table also notes valuation related data points around recent royalty investments by 3rd-party investors. Some believe these 3rd-party investments provide a barometer around product valuation. MIST's royalty financing was transacted before MIRT received a refusal to file letter from the FDA for its Etripamil NDA submission. As best we can tell, MIST's royalty financing commitment is still active. KALV & HUMA share prices are down 10%+ from recent third-party stock purchases within the last month. MIST & KALV trade at the lowest FY2027 revenue multiples. This is not investment advice. None of the 4 profiled have any FDA approved products & could go bankrupt if their filings are not approved. As always, we do not use automation so there may be inadvertent mistakes in the raw data $XBI

User Image Carlito84 Posted - 1 week ago

$KALV bought more 🔥

User Image CliffordCapital Posted - 1 week ago

$KALV loading more here soon

User Image AdiDasRom Posted - 1 week ago

$KALV

User Image TwongStocks Posted - 1 week ago

$KALV Another institution reports a significant position. https://www.sec.gov/Archives/edgar/data/1348911/000090266424006561/p24-3216sc13g.htm Vestal Point Capital owns 4m shares, 9.3%

User Image Carlito84 Posted - 1 week ago

$KALV added

User Image TwongStocks Posted - 1 week ago

$KALV "CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 3,374,064 shares or 7.8% of the 43,215,472 shares believed to be outstanding. " https://www.sec.gov/Archives/edgar/data/1348911/000142284924000097/SEC13G_Filing.htm

User Image Friesenkoei Posted - 1 week ago

$KALV 5% after market spike? What's up?

User Image Carlito84 Posted - 1 week ago

$KALV bought more

User Image TwongStocks Posted - 1 week ago

$KALV KalVista Pharmaceuticals to Present at Upcoming Investor Conferences https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-present-upcoming-investor-conferences-5 • Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:10 a.m. EST • Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 11:00 a.m. GMT Each presentation will be live webcast on the Company’s website. After the presentations, an audio archive will be available on KalVista’s website for 30 days.

User Image CliffordCapital Posted - 1 week ago

$KALV bought some

User Image Night_Owl_Biotech Posted - 2 weeks ago

$KALV announced a royalty financing with DRI on its sebetralstat therapy for HAE with a 6/17/2025 PDUFA date. DRI committed $100MM in exchange for a 5% royalty on sebetralstat sales. Using simple math, this transaction by itself suggests a $2.0B sebetralstat valuation. KALV's market cap is just under $500MM. This is not investment advice because this simple comparison has many flaws & does not consider dozens of other valuation considerations. More important, if the FDA does not approve sebetralstat then KALV could go bankrupt & shareholders could lose 100% of their investment. The attachment compares the KALV/DRI royalty financing agreement with peer transactions of FDA approved therapies (though $IBRX & $VRNA therapies were not approved at the time of their respective agreements). Please let us know if we are missing any FY2024 royalty financing agreements on FDA approved therapies (or those with PDUFA like $SNDX). $ASND As always, our analysis could be wrong.

User Image MakingDreamsReality Posted - 2 weeks ago

PM mOOvers 👀 $BA - Boeing shares are trading higher after machinists voted to accept a new contract, ending the strike. $ESLT -Elbit Systems Awarded Follow-On $127M Contract For Iron Fist APS, Supporting Bradley IFV Upgrades Over 34-Month Period $ZCAR - Zoomcar Doubles Customer Support Team To Enhance Guest and Host Experience $KALV - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) $AZPN - Emerson offers to buy rest of AspenTech for $240/share in cash, Aspen Technology Q1 2025 Adj EPS $0.85 May Not Compare To $1.57 Estimate, Sales $215.90M Miss $267.63M Estimate

User Image maphere Posted - 2 weeks ago

$BCRX $KALV got money today for their HAE treatment, not sure if that's affecting us even though it's not a .prophy

User Image RollingDollars Posted - 2 weeks ago

$KALV

User Image briefingcom Posted - 2 weeks ago

$KALV: KalVista Pharmaceuticals priced an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00/share to certain investors https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241104071109KALV&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image TwongStocks Posted - 2 weeks ago

$KALV $100m royalty agreement signed with DRI Healthcare. https://www.sec.gov/ix?doc=/Archives/edgar/data/1348911/000119312524250223/d904891d8k.htm KALV receives $100m upfront. DRI receives 5% royalty on annual sebetralstat up to $500m. 1.10% royalty on annual sales of $500m-$750m. $0.25% royalty on annual sales above $750m. If sebetralstat is approved by September 30, 2025, KALV can receive an optional payment of $22m from DRI. If KALV elects the optional $22m payment, DRI's 5% royalty increases to 6%.

User Image DonCorleone77 Posted - 2 weeks ago

$KALV KalVista 5.5M share Secondary priced at $10.00 Jefferies, BofA, TD Cowen and Stifel acted as joint book running managers for the offering.

User Image TwongStocks Posted - 10/29/24

$KALV -Phase 3 trial data show that early treatment is correlated with shorter attack duration -Rigorous comparison of Phase 3 results for oral sebetralstat and pivotal trial results of IV recombinant C1-inhibitor for on-demand treatment of HAE attacks shows no differences in time to beginning of symptom relief https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-presents-new-sebetralstat-data-2024 Hopefully, continues to move upward as it gets closer to the PDUFA date.

User Image briefingcom Posted - 10/28/24

$KALV: KalVista Pharmaceuticals presents new sebetralstat data at the 2024 American College of Allergy Asthma and Immunology https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241028063154KALV&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image Fugazi_ Posted - 1 month ago

$KALV what do people expect on moves, KALV went to 40$ during their phase 3 data announcement in 2021 for KVD900 oral

User Image justiceforb_85 Posted - 1 month ago

$KALV looking forward to PDUFA! https://www.nejm.org/doi/full/10.1056/NEJMoa2314192

User Image uptrend98 Posted - 1 month ago

$KALV this about to blow up or what?

User Image pepe7 Posted - 1 month ago

$KALV

User Image shared_alerts Posted - 09/30/24

-09/30/2024- 📉 SCANNER UPDATE📈 $MNPR $CNEY $KALV $LZM ↩️

User Image AdiDasRom Posted - 09/30/24

$KALV "KalVista Announces Submission of Additional Marketing Authorization Applications for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema"

User Image pepe7 Posted - 09/29/24

$KALV

User Image GambitMentality Posted - 09/27/24

Today’s #StockMarket EOD Biggest Gainers by %, led by $KALV $JG and $PGHL to lead the TOP 3

User Image monzelo Posted - 09/27/24

$KALV Hasta Kalvista..baby

Analyst Ratings
Jones Trading Buy Sep 27, 24
Cantor Fitzgerald Overweight Sep 9, 24
HC Wainwright & Co. Buy Sep 6, 24
Needham Buy Sep 6, 24
HC Wainwright & Co. Buy Jul 15, 24
Needham Buy Jul 12, 24
Needham Buy Jun 18, 24
HC Wainwright & Co. Buy May 3, 24
Needham Buy May 1, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Crockett Thomas Andrew CEO CEO Feb 01 Sell 16.49 10,000 164,900 117,532 02/05/24
Venrock Healthcare Capital Par... Director Director Jan 30 Buy 14.47 88,099 1,274,793 4,738,683 02/01/24
Venrock Healthcare Capital Par... Director Director Jan 25 Buy 13.31 91,804 1,221,911 4,650,584 01/29/24
Venrock Healthcare Capital Par... Director Director Jan 22 Buy 12.51 99,129 1,240,104 4,558,780 01/24/24
Venrock Healthcare Capital Par... 10% Owner 10% Owner Jan 17 Buy 12.51 143,605 1,796,499 4,459,651 01/19/24
Venrock Healthcare Capital Par... 10% Owner 10% Owner Jan 11 Buy 12.71 26,246 333,587 4,316,046 01/16/24
Venrock Healthcare Capital Par... 10% Owner 10% Owner Jan 08 Buy 12.56 137,700 1,729,512 4,289,800 01/10/24
Feener Edward P. Chief Scientific Off.. Chief Scientific Officer Jan 08 Sell 13 17,321 225,173 62,507 01/10/24
Venrock Healthcare Capital Par... 10% Owner 10% Owner Dec 27 Buy 12.32 519,017 6,394,289 4,092,731 12/29/23
Audhya Paul K. Chief Medical Office.. Chief Medical Officer Nov 17 Sell 8.23 7,985 65,717 36,568 11/21/23
Feener Edward P. Chief Scientific Off.. Chief Scientific Officer Nov 17 Sell 8.23 4,958 40,804 79,828 11/21/23
Yea Christopher Chief Development Of.. Chief Development Officer Nov 17 Sell 8.23 7,113 58,540 46,046 11/21/23
Audhya Paul K. Chief Medical Office.. Chief Medical Officer Aug 17 Sell 10.73 8,020 86,055 26,023 08/21/23
Feener Edward P. Chief Scientific Off.. Chief Scientific Officer Aug 17 Sell 10.73 4,976 53,392 73,289 08/21/23
Yea Christopher Chief Development Of.. Chief Development Officer Aug 17 Sell 10.73 7,142 76,634 41,662 08/21/23
Palleiko Benjamin L President, CFO, CBO.. President, CFO, CBO & Sec'y Aug 17 Sell 10.73 13,067 140,209 95,254 08/21/23
Crockett Thomas Andrew CEO CEO Aug 17 Sell 10.73 14,876 159,619 146,756 08/21/23
Yea Christopher Chief Development Of.. Chief Development Officer Jan 11 Sell 10.14 2,604 26,405 37,310 05/19/23
Palleiko Benjamin L President, CFO, CBO.. President, CFO, CBO & Sec'y Jan 11 Sell 10.14 4,037 40,935 78,126 05/19/23
Feener Edward P. Chief Scientific Off.. Chief Scientific Officer Jan 11 Sell 10.14 1,786 18,110 66,771 05/19/23
Crockett Thomas Andrew CEO CEO Jan 11 Sell 10.14 5,627 57,058 128,050 05/19/23
Audhya Paul K. Chief Medical Office.. Chief Medical Officer Jan 11 Sell 10.14 2,780 28,189 13,014 05/19/23
Audhya Paul K. Chief Medical Office.. Chief Medical Officer Aug 17 Sell 14.96 725 10,846 1,693 08/19/22
Feener Edward P. Chief Scientific Off.. Chief Scientific Officer Aug 17 Sell 14.96 532 7,959 61,132 08/19/22
Yea Christopher Chief Development Of.. Chief Development Officer Aug 17 Sell 14.96 1,145 17,129 33,597 08/19/22
Palleiko Benjamin L CFO, CBO & Secretary CFO, CBO & Secretary Aug 17 Sell 14.96 725 10,846 66,693 08/19/22
Crockett Thomas Andrew CEO CEO Aug 17 Sell 14.96 1,797 26,883 112,178 08/19/22
Crockett Thomas Andrew CEO CEO Mar 09 Sell 17.0693 10,000 170,693 114,670 03/11/22